Demars Financial Group LLC Has $772,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

Demars Financial Group LLC lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 80.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 15,051 shares of the biopharmaceutical company’s stock after selling 62,519 shares during the period. Bristol-Myers Squibb accounts for approximately 0.4% of Demars Financial Group LLC’s holdings, making the stock its 24th largest position. Demars Financial Group LLC’s holdings in Bristol-Myers Squibb were worth $772,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb during the third quarter valued at $25,000. Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the period. Legacy Financial Group LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $39,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY opened at $49.03 on Wednesday. The firm has a fifty day moving average price of $51.22 and a 200-day moving average price of $51.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The stock has a market cap of $99.37 billion, a PE ratio of 12.69, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. During the same period in the prior year, the company posted $1.82 earnings per share. The company’s revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.89%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.18%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BMY shares. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.